ANI PHARMACEUTICALS INC

# Signal Note: Driehaus Capital Initiates $6.0M Position in ANIP Driehaus's entry into ANIP suggests conviction in the company's generic/specialty pharma portfolio, likely driven by recent FDA approvals or upcoming exclusivity-period drugs with limited competition. The $6.0M position size (modest for the fund) indicates a selective bet rather than a core conviction, potentially targeting near-term cash flow generation or M&A candidacy in the consolidating generic space. Monitor for Q3/Q4 catalyst catalogs (new product launches, pricing actions) and sector M&A activity, as ANIP's smaller scale makes it an acquisition target for larger players seeking revenue diversification.